News

Zymeworks Authorized To Buy Back Up To $200 Mln Of Shares

NASDAQ

(RTTNews) - Zymeworks Inc. (ZYME), a biotechnology company, said Monday that its Board has authorized a second share repurchase program of up to $200 million, which is expected to begin before the end of 2026 and run through 2028.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.